Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.90 Insider Own9.60% Shs Outstand132.64M Perf Week-3.03%
Market Cap42.44M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float119.91M Perf Month-53.76%
Income-76.95M PEG- EPS next Q-0.15 Inst Own31.25% Short Float / Ratio6.89% / 4.42 Perf Quarter-72.41%
Sales0.67M P/S63.35 EPS this Y37.90% Inst Trans27.31% Short Interest8.26M Perf Half Y-85.25%
Book/sh0.00 P/B94.12 EPS next Y27.27% ROA-66.32% Target Price4.00 Perf Year-75.38%
Cash/sh0.48 P/C0.67 EPS next 5Y- ROE-1103.79% 52W Range0.22 - 2.51 Perf YTD-75.19%
Dividend- P/FCF- EPS past 5Y-9.78% ROI-91.50% 52W High-87.25% Beta1.13
Dividend %- Quick Ratio3.20 Sales past 5Y0.00% Gross Margin-152.45% 52W Low46.52% ATR0.05
Employees146 Current Ratio3.32 Sales Q/Q- Oper. Margin-11438.78% RSI (14)29.51 Volatility8.15% 17.29%
OptionableYes Debt/Eq224.26 EPS Q/Q95.86% Profit Margin-11434.03% Rel Volume0.72 Prev Close0.33
ShortableYes LT Debt/Eq220.32 EarningsNov 14 BMO Payout- Avg Volume1.87M Price0.32
Recom1.00 SMA20-12.24% SMA50-51.30% SMA200-74.94% Volume1,338,300 Change-1.84%
Date Action Analyst Rating Change Price Target Change
Nov-01-21Initiated Alliance Global Partners Buy $11
Jul-01-20Initiated Evercore ISI Outperform
May-26-20Initiated Piper Sandler Overweight $13
Apr-27-20Initiated H.C. Wainwright Buy $15
Nov-26-18Initiated Needham Buy $23
Nov-21-18Initiated Oppenheimer Outperform $15
Nov-20-18Initiated RBC Capital Mkts Outperform $20
Nov-27-23 08:11PM
Nov-20-23 08:00AM
Nov-15-23 09:15AM
Nov-14-23 07:30AM
07:00AM Loading…
Nov-04-23 08:00AM
Nov-01-23 08:00AM
Oct-16-23 04:39PM
Oct-09-23 02:00PM
Oct-02-23 08:00AM
Sep-28-23 08:00AM
Sep-27-23 04:30PM
Aug-31-23 08:00AM
Aug-15-23 02:30AM
07:27AM Loading…
Aug-14-23 07:27AM
Aug-01-23 08:00AM
Jul-11-23 08:00AM
Jul-10-23 02:00PM
Jun-20-23 09:55AM
Jun-14-23 04:30PM
Jun-09-23 09:55AM
May-31-23 04:30PM
May-22-23 08:00AM
May-17-23 07:27AM
May-15-23 04:18PM
May-11-23 05:20PM
07:24AM Loading…
Apr-20-23 07:24AM
Apr-19-23 08:15AM
Apr-18-23 07:16PM
Apr-17-23 04:16PM
Mar-29-23 07:28AM
Mar-28-23 02:12PM
Mar-27-23 07:00AM
Mar-20-23 04:30PM
Mar-12-23 10:10AM
Mar-07-23 08:00AM
Feb-18-23 12:30PM
Jan-16-23 12:00PM
Dec-12-22 07:00AM
Nov-23-22 08:00AM
Nov-21-22 04:52PM
Nov-14-22 07:00AM
Nov-10-22 08:00AM
Nov-07-22 08:00AM
Nov-03-22 09:07AM
Oct-10-22 07:00AM
Sep-29-22 07:00AM
Sep-28-22 12:08AM
Sep-27-22 04:06PM
Sep-22-22 05:27AM
Sep-19-22 07:00AM
Sep-12-22 08:00AM
Aug-15-22 03:00PM
Aug-10-22 07:00AM
Aug-09-22 10:39AM
Aug-08-22 08:00AM
Aug-04-22 07:29AM
Aug-01-22 07:00AM
Jun-13-22 07:00AM
Jun-10-22 07:00AM
Jun-02-22 07:00AM
Jun-01-22 04:30PM
May-17-22 04:30PM
May-10-22 07:00AM
May-05-22 03:36PM
May-03-22 08:00AM
Apr-27-22 12:31PM
Apr-26-22 09:20AM
Apr-25-22 08:00PM
Apr-21-22 08:05AM
Apr-20-22 04:05PM
Apr-07-22 08:00AM
Mar-30-22 07:43AM
Mar-29-22 10:12AM
Mar-28-22 11:07AM
Mar-25-22 02:29PM
Mar-24-22 01:57PM
Mar-23-22 08:28AM
Mar-21-22 01:04PM
Mar-15-22 12:01PM
Mar-11-22 11:27AM
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.